» Articles » PMID: 39598090

Disparities in the Prevalence of Hospitalizations and In-Hospital Mortality Due to Acute Myocardial Infarction Among Patients with Non-Alcoholic Fatty Liver Disease: A Nationwide Retrospective Study

Overview
Journal J Clin Med
Specialty General Medicine
Date 2024 Nov 27
PMID 39598090
Authors
Affiliations
Soon will be listed here.
Abstract

Non-alcoholic liver disease (NAFLD) may be associated with cardiovascular diseases; however, only a few studies have analyzed this relationship. We aimed to assess the epidemiologic data and the association between NAFLD and acute myocardial infarction (AMI) in the United States. The National Inpatient Sample (NIS) database 2016-2019 was queried using ICD10-CM diagnostic codes to identify hospitalizations of AMI + NAFLD. Essential demographic variables were analyzed to determine the disparities in the prevalence of AMI hospitalizations and deaths among NAFLD patients. Univariate and multivariate logistic regression models determined the association between NAFLD and AMI hospitalizations and death. Among the total 5450 NAFLD patients hospitalized with AMI, 5.11% (279) died. Females were less likely to be admitted and die due to AMI than males. Younger patients (<50) were less likely to be hospitalized and die than those ≥50. Compared to the white population, black patients were less likely; however, Hispanics, Asians, and Pacific Islanders were more likely to be hospitalized. Race was not found to affect hospital mortality. On multivariate analysis, NAFLD was associated with higher odds of AMI hospitalization [OR 1.55, 95% CI 1.51-1.60, < 0.01] and death [OR 1.96, 95% CI 1.74-2.21, < 0.01]. Older white males with NAFLD had a higher prevalence of AMI hospitalizations and mortality.

References
1.
Targher G, Byrne C, Lonardo A, Zoppini G, Barbui C . Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. J Hepatol. 2016; 65(3):589-600. DOI: 10.1016/j.jhep.2016.05.013. View

2.
Stahl E, Dhindsa D, Lee S, Sandesara P, Chalasani N, Sperling L . Nonalcoholic Fatty Liver Disease and the Heart: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019; 73(8):948-963. DOI: 10.1016/j.jacc.2018.11.050. View

3.
Ipsen D, Lykkesfeldt J, Tveden-Nyborg P . Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell Mol Life Sci. 2018; 75(18):3313-3327. PMC: 6105174. DOI: 10.1007/s00018-018-2860-6. View

4.
Kaelber D, Foster W, Gilder J, Love T, Jain A . Patient characteristics associated with venous thromboembolic events: a cohort study using pooled electronic health record data. J Am Med Inform Assoc. 2012; 19(6):965-72. PMC: 3534456. DOI: 10.1136/amiajnl-2011-000782. View

5.
Liu Y, Xu W, Zhai T, You J, Chen Y . Silibinin ameliorates hepatic lipid accumulation and oxidative stress in mice with non-alcoholic steatohepatitis by regulating CFLAR-JNK pathway. Acta Pharm Sin B. 2019; 9(4):745-757. PMC: 6664044. DOI: 10.1016/j.apsb.2019.02.006. View